p38 mitogen-activated protein kinase (p38 MAPK) and transforming growth factor-beta (TGF-β) signaling pathway (p38 MAPK/TGF-β signaling)

The p38 mitogen-activated protein kinase (MAPK) and transforming growth factor-beta (TGF-β) signaling pathways are fundamental regulatory networks that coordinate cellular responses to environmental stress and cytokine stimulation. TGF-β signaling is bifurcated into canonical Smad-dependent pathways and non-canonical pathways, where p38 MAPK serves as a key integrator that modulates cellular outcomes such as apoptosis, differentiation, and epithelial-mesenchymal transition (EMT) [5, 10]. This signaling axis is frequently dysregulated in chronic diseases; for instance, its overactivation drives the progression of tissue fibrosis and promotes a pro-metastatic environment in advanced cancers [6, 8]. Pharmacological targeting of this axis primarily focuses on inhibiting p38 MAPK isoforms or the TGF-β type I receptor (ALK5) to attenuate pathological gene expression and cellular transformations [1, 2, 3]. Despite the therapeutic promise, clinical translation is complicated by the essential roles these pathways play in normal physiology, resulting in significant safety concerns such as cardiotoxicity and the development of cutaneous lesions [9, 11].

Other names

p38-TGFB crosstalkNon-canonical TGF-beta signalingp38 MAPK pathwayTGF-beta signaling pathwayTGFB-p38 axisp38 mitogen-activated protein kinase signalingTransforming growth factor-beta signaling

The mechanism involves the pharmacological inhibition of p38 mitogen-activated protein kinase (specifically the alpha isoform, MAPK14) or the transforming growth factor-beta receptor type 1 (TGFBR1/ALK5). By blocking these nodes, drugs prevent the phosphorylation of downstream effectors such as Smad2/3 and various transcription factors (e.g., ATF2, CHOP), thereby inhibiting the expression of genes involved in inflammation, fibrosis, and tumor progression [1, 5, 9].